Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANS “Ready” For Neuro-Stimulating Competition With Advanced Bionics

This article was originally published in The Gray Sheet

Executive Summary

Advanced Neuromodulation Systems is girding for Boston Scientific subsidiary Advanced Bionics' full-scale launch of the Precision rechargeable spinal cord stimulator, expecting to be without a competing rechargeable system until 2005

You may also be interested in...



NuVasive Facility Expansion Triples Capacity; Stock Up 24% In January

Spinal surgery system maker NuVasive's recently expanded production, training and warehousing capacity is spurring investor optimism that drove a 24.3% stock price increase in January to $12.7

NuVasive Facility Expansion Triples Capacity; Stock Up 24% In January

Spinal surgery system maker NuVasive's recently expanded production, training and warehousing capacity is spurring investor optimism that drove a 24.3% stock price increase in January to $12.7

Pipeline Technologies In Brief

Medtronic diabetes care update: Firm will initiate full market release of its Guardian continuous glucose monitoring system, PMA-approved in January, into the $3 bil. blood glucose monitoring market by February 2005, CFO Bob Ryan notes Dec. 1 at the Lazard Life Sciences Conference in New York. In FY 2006, Medtronic plans to launch the next-generation Guardian RT, capable of displaying a patient's "real time" glucose value in five-minute intervals, he added. The company expects to integrate Guardian RT with its Paradigm sensor-augmented insulin pump technology, as part of the effort to develop a closed-loop, external artificial pancreas for diabetic patients by 2008 (1"The Gray Sheet" June 21, 2004, p. 26). Ryan also reported Medtronic is conducting a clinical trial to drive insulin pump therapy penetration. The study will compare insulin pumps with multiple daily injections. The exec believes that a device capable of dropping the HbA1c levels in Type 1 diabetic patients to 7% could lower diabetes healthcare costs by $100 bil. over the next 10 years...

Related Content

UsernamePublicRestriction

Register

MT020639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel